Biomarkers: The Future

Critical Care Clinics

Volumn 27, Issue 2, 2011, Pages 407-419

  LaRosa, Steven P ^a,b   Opal, Steven M ^a,c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Biomarkers; Gene expression; Genomics; Proteomics; Sepsis; Theragnostics

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CYTOKINE INDUCIBLE SRC HOMOLOGY DOMAIN PROTEIN; ENDOTOXIN; ERITORAN; GELSOLIN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HLA DR ANTIGEN; INTER ALPHA INHIBITOR PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 6; MANNOSE BINDING LECTIN; MYELOID DIFFERENTIATION FACTOR ADAPTOR LIKE PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMYXIN; PROTEIN; PROTEIN C; SERINE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TORAYMYXIN; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO ACID SUBSTITUTION; ANTIINFLAMMATORY ACTIVITY; BODY FLUID; CAPILLARY LEAK SYNDROME; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENDOTHELIUM CELL; ENDOTOXEMIA; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENOMICS; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNE DEFICIENCY; IMMUNOASSAY; INNATE IMMUNITY; INTENSIVE CARE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEOMICS; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURFACE PLASMON RESONANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSCRIPTOMICS;

ALPHA-GLOBULINS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CRITICAL CARE; ENDOTOXINS; GELSOLIN; GENE EXPRESSION; HLA-DR ANTIGENS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOMICS; SEPSIS;

EID: 79953002955     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.12.012     Document Type: Review

References (74)

1. Santos A.A., Wilmore D.W. The systematic inflammatory response: perspective of human endotoxemia. Shock 1996, 6:S50-S56.
2. Opal S.M., Scannon P.J., Vincent J.L., et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999, 180:1584-1589.
3. Cohen J. The detection and interpretation of endotoxemia. Intensive Care Med 2000, 26:S51-S56.
4. Bates D.W., Parsommet J., Ketchum P.A., et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. Clin Infect Dis 1998, 27:582-591.
5. Marshall J.C., Walker P.M., Foster D.M., et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 2002, 6:342-348.
6. Klein D. Clinical assessment does not predict endotoxemia in septic shock [abstract 469]. In: Programs and abstracts of the Society of Critical Care Medicine. Miami (FL), January 9-13, 2010.
7. Lynn M., Rossignol D.P., Wheeler J.L., et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003, 187:631-639.
8. Tidswell M., Tillis W., LaRosa S.P., et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010, 38:72-83.
9. Cruz D.N., Perazella M.A., Bellomo R., et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007, 11:R47.
10. Aird W.C. The role of the endothelium in severe sepsis and multiple organ dysfunction. Blood 2003, 101:3765-3777.
11. Gamble J.R., Drew J., Trezise L., et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000, 87:603-607.
12. Scharpfenecker M., Fiedler U., Reiss Y., et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2004, 118:771-780.
13. Fiedler U., Reiss Y., Scharpfenecker M., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
14. Siner J.M., Bhandari V., Engle K.M. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 2009, 31:348-353.
15. Kumpers P., Lukasz A., David S., et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008, 12:R147.
16. Parikh S.M., Mammoto T., Schultz A., et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46.
17. Witzenbichler B., Westermann D., Knueppel S., et al. Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005, 111:97-105.
18. Minhas N., Xue M., Fukudome K., et al. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 2010, 24:873-881.
19. Haddad J.G., Harper K.D., Guoth M., et al. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci U S A 1990, 87:1381-1385.
20. Bucki R., Levental I., Kulakowska A., et al. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008, 9:541-551.
21. Lee P.S., Drager L.R., Stossel T.P., et al. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg 2006, 243:399-403.
22. Lee P.S., Patel S.R., Christiani D.C., et al. Plasma gelsolin depletion and circulating actin in sepsis-a pilot study. PLoS One 2008, 3:e3712.
23. Lee P.S., Waxman A.B., Cotich K.L. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007, 35:849-852.
24. Salier J., Rouet P., Raguenez G., et al. The inter-alpha-inhibitor family: from structure to regulation. Biochem J 1996, 315:1-9.
25. Lim Y.P., Bendelja K., Opal S.M., et al. Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. J Infect Dis 2003, 188:919-926.
26. Opal S.M., Lim Y.P., Siryaporn E., et al. Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis. Crit Care Med 2007, 35:387-392.
27. Fries E., Blum A. Bikunin-not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 2000, 32:125-137.
28. Wakahara K., Kobayashi H., Yagyu T., et al. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor-α and interleukin-1β in macrophages. J Infect Dis 2005, 191:930-938.
29. Fries E., Kaczmarczyk A. Inter-α-inhibitor, hyaluronan and inflammation. Acta Biochim Pol 2003, 50:735-742.
30. Yang S., Lim Y.P., Zhou M., et al. Administration of human inter-a-inhibitors maintains homodynamic stability and improves survival during sepsis. Crit Care Med 2002, 30:617-622.
31. Wu R., Cui X., Lim Y.P., et al. Delayed administration of human inter-α inhibitor proteins reduces mortality in sepsis. Crit Care Med 2004, 32:1747-1752.
32. Volk H.D., Reinke P., Docke W.D. Clinical aspects: from systemic inflammation to immunoparalysis. Chem Immunol 2000, 74:162-177.
33. Volk H.D., Reinke P., Krausch D., et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996, 22:S474-S481.
34. Kox W.J., Bone R.C., Krausch D., et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. Arch Intern Med 1997, 157:389-393.
35. Docke W.D., Hoflich C., Davis K.A. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005, 51:2341-2347.
36. Lukaszewicz A.C., Grienay M., Resche-Rigon M., et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009, 37:2746-2752.
37. Strohmeyer J.C., Blume C., Meisel C. Standardized immune monitoring for the prediction of infections after cardiopulmonary bypass surgery in risk patients. Cytometry B Clin Cytom 2003, 53:54-62.
38. Meisel C., Schefold J.C., Pschowski R., et al. Granulocyte-microphage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med 2009, 180:640-648.
39. Hotchkiss R.S., Opal S.M. Immunotherapy for sepsis: a new approach against an ancient foe. N Engl J Med 2010, 363(1):87-89.
40. Sutherland A.M., Walley R. Bench-to-bedside review: association of genetic variation with sepsis. Crit Care 2009, 13:210.
41. Ashley E.A., Butte A.J., Wheeler M.T., et al. Clinical assessment incorporating a personal genome. Lancet 2010, 375:1525-1535.
42. Choi M., Scholl U.I., Ji W., et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A 2009, 106:19096-19101.
43. Pushkarev D., Neff N.F., Quake S.R. Single-molecule sequencing of an individual human genome. Nat Biotechnol 2009, 27:847-852.
44. Samani N.J., Tomaszewski M., Schunkert H. The personal genome-the future of personalized medicine. Lancet 2010, 375:1497-1498.
45. Ormond K.E., Wheeler M.T., Hudgins L., et al. Challenges in the clinical application of whole-genome sequencing. Lancet 2010, 375:1749-1751.
46. Sorensen T.I., Nielson G.G., Andersen P.K., et al. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988, 318:727-732.
47. Burgner D., Levin M. Genetic susceptibility to infectious diseases. Pediatr Infect Dis J 2003, 22:1-6.
48. Varmus H. Ten years on-the human genome and medicine. N Engl J Med 2010, 362(21):2028-2029.
49. Akey J.M., Eberle M.A., Rieder M.J., et al. Population history and natural selection shape patterns of genetic variation in 132 genes. PLoS Biol 2004, 2:e286.
50. Luyendyk J.P., Schabbauer G.A., Tencati M., et al. Genetic analysis of the role of the P13K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol 2008, 180:4218-4226.
51. Stenson P.D., Mort M., Ball E.V., et al. The human gene mutation database: 2008 update. Genome Med 2009, 1:13.
52. Jegga A.G., Gowrisankar S., Chen J., et al. PolyDoms: a whole genome database for the identification of non-synonymous coding SNPs with the potential to impact disease. Nucleic Acids Res 2007, 35:D700-D706.
53. The International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320.
54. Klein T.E., Chang J.T., Cho M.K., et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. PharmaGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001, 1:167-170.
55. Feero W.G., Guttmacher A.E., Collins F.S. Genomic medicine-an updated primer. N Engl J Med 2010, 362:2001-2011.
56. van der Poll T., Opal S.M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374:1543-1556.
57. Khor C.C., Chapman S.J., Vannberg F.O., et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007, 39:523-528.
58. Ku C.L., Bernuth H., Picard C., et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007, 204:2407-2422.
59. Khor C.C., Phil D., Vannberg F.O., et al. CISH and susceptibility to infectious diseases. N Engl J Med 2010, 362:2092-2101.
60. Cobb J.P., Stormo G.D., Morrissey J.J., et al. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays. Crit Care Med 2002, 30(12):2711-2721.
61. Tang B.M., McLean A.S., Dawes I.W., et al. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009, 37(3):882-888.
62. Calvano S.E., Xiao W., Richards D.R., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
63. Johnson S.B., Lissauer M.E., Bochicchio G.V., et al. Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 2007, 245(4):611-621.
64. Lissauer M.E., Johnson S.B., Bochicchio G.V., et al. Differential expression of toll-like receptor genes: sepsis compared with sterile inflammation 1 day before sepsis diagnosis. Shock 2009, 31(3):238-244.
65. Karvunidis T., Mares J., Thongboonkerd V., et al. Recent progress of proteomics in critical illness. Shock 2009, 31:545-552.
66. Nguyen A., Yaffe M.B. Proteomics and systems biology approaches to signal transduction in sepsis. Crit Care Med 2003, 31(Suppl 1):S1-S6.
67. Sigdel T.K., Sarwal M.M. The proteogenomic path toward biomarker discovery. Pediatr Transplant 2008, 12:737-747.
68. Hodgetts A., Levin M., Kroll J.S., et al. Biomarker discovery in infectious diseases using SELD1. Future Microbiol 2007, 2:35-49.
69. Paugam-Burtz C., Albuquerque M., Baron G., et al. Plasma proteome to look for diagnostic biomarkers of early bacterial sepsis after liver transplantation: a preliminary study. Anesthesiology 2010, 112:926-935.
70. Service R.F. Proteomics. Will biomarkers take off at last?. Science 2008, 321:1760.
71. Kalenka A., Feldmann R.E., Otero K., et al. Changes in the serum proteome of patients with sepsis and septic shock. Anesth Analg 2006, 103:1522-1526.
72. Buhimschi C.S., Bhandari V., Hamar B.D., et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection and neonatal sepsis. PLoS Med 2007, 4(1):e18.
73. Macquire P.B., Fitzgerald D.J. Platelet proteomics. J Thromb Haemost 2003, 1:1593-1601.
74. Levi M., Opal S.M. Coagulation abnormalities in critically ill patients. Crit Care 2006, 10:222-228.